Advertisement
Screener

Trevi Therapeutics, Inc. (TRVI) Graph

TRVI Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $15.15M; Operating expenses $20.51M; Income tax -$19.00K; Net income -$17.80M.
  • 2026-03-31: Research and development $9.94M; Operating expenses $14.91M; Income tax -$20.00K; Net income -$13.19M.
  • 2025-12-31: Research and development $6.19M*; Operating expenses $10.22M*; Income tax -$16.00K*; Net income -$8.32M*.
  • 2025-09-30: Research and development $10.09M; Operating expenses $13.92M; Income tax -$15.00K; Net income -$11.80M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$15.15M$20.51M-$19.00K-$17.80M
2026-03-31$9.94M$14.91M-$20.00K-$13.19M
2025-12-31$6.19M*$10.22M*-$16.00K*-$8.32M*
2025-09-30$10.09M$13.92M-$15.00K-$11.80M
2025-06-30$9.39M$13.72M-$21.00K-$12.30M
2025-03-31$7.81M$11.47M-$11.00K-$10.34M
2024-09-30$11.22M$14.09M-$31.00K-$13.24M
2024-06-30$10.02M$13.29M-$8.00K-$12.35M
2024-03-31$8.80M$11.91M-$8.00K-$10.90M
2023-09-30$6.32M$9.04M-$13.00K-$7.70M
2023-06-30$5.84M$8.38M-$30.00K-$7.14M
2023-03-31$5.00M$7.56M-$7.00K-$6.40M
2022-09-30$5.77M$8.40M-$7.00K-$8.27M
2022-06-30$5.10M$7.82M-$4.00K-$8.05M
2022-03-31$4.64M$7.03M-$5.00K-$7.33M
2021-09-30$4.72M$6.95M$2.00K-$7.25M
2021-06-30$6.50M$9.17M-$2.00K-$9.79M
2021-03-31$5.59M$8.09M-$15.00K-$8.37M
2020-09-30$4.83M$7.24M-$11.00K-$7.38M
2020-06-30$4.92M$7.41M-$15.00K-$7.38M
2020-03-31$6.02M$8.64M-$9.00K-$8.47M
2019-09-30$5.65M$7.65M-$5.00K-$7.37M
2019-06-30$5.53M$7.42M-$5.00K-$7.35M
2019-03-31$3.34M$4.81M-$4.00K-$4.80M
2018-09-30$3.75M$4.96M-$25.00K-$5.65M
2018-06-30$3.44M$4.38M-$25.00K-$4.86M
2018-03-31$2.36M$3.14M-$25.00K-$4.05M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$25.09M$35.42M-$39.00K-$30.99M
2025-06-30$17.20M$25.19M-$32.00K-$22.64M
2024-06-30$18.82M$25.20M-$16.00K-$23.25M
2023-06-30$10.84M$15.95M-$37.00K-$13.55M
2022-06-30$9.75M$14.85M-$9.00K-$15.38M
2021-06-30$12.09M$17.26M-$17.00K-$18.16M
2020-06-30$10.94M$16.05M-$24.00K-$15.86M
2019-06-30$8.87M$12.23M-$9.00K-$12.15M
2018-06-30$5.80M$7.52M-$50.00K-$8.91M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$27.29M$39.11M-$48.00K-$34.44M
2024-09-30$30.05M$39.28M-$46.00K-$36.50M
2023-09-30$17.16M$24.99M-$50.00K-$21.24M
2022-09-30$15.52M$23.25M-$16.00K-$23.65M
2021-09-30$16.80M$24.20M-$15.00K-$25.42M
2020-09-30$15.77M$23.30M-$35.00K-$23.23M
2019-09-30$14.52M$19.88M-$14.00K-$19.51M
2018-09-30$9.55M$12.48M-$75.00K-$14.56M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$33.48M$49.33M-$64.00K-$42.76M
2024-12-31$39.38M$51.52M-$30.00K-$47.91M
2023-12-31$23.68M$33.92M-$32.00K-$29.07M
2022-12-31$19.83M$29.91M-$36.00K-$29.15M
2021-12-31$22.98M$32.48M-$21.00K-$33.94M
2020-12-31$22.33M$32.49M-$18.00K-$32.76M
2019-12-31$19.34M$26.64M-$18.00K-$26.05M
2018-12-31$14.07M$18.41M-$124.00K-$20.55M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12